![realDaveFeldman's tweet photo. I want to share a crucial update on our study, KETO-CTA.
(The video for this article is in the next tweet)
Our study recruited 100 participants, each undergoing two high-resolution heart scans, known as CT angiograms, one year apart. (For more background on this study design, see preprint in the following tweet)
There are now four analyses of those same 200 scans. But one of those analyses stands out — and I have some new developments to report.
For a quick background, the first quantitative analysis was from an AI company, Cleerly. We published their analysis of our scans last year.
After the paper was published, the Citizen Science Foundation was free to look at the raw Cleerly data, and we found a number of patterns that appeared different from what is typically seen in other coronary plaque studies.
For example, in Cleerly's analysis, not one of the participants showed lower plaque levels at follow-up — even though CTA scans typically show some natural variation in both directions, especially in people who start with very little plaque.
For another example within their data, people with no detectable calcium in their scans appeared to have several times more plaque progression than those who already had some calcium present. This runs counter to what many in cardiology call the "power of zero" — the well-established finding that having no coronary calcium is typically associated with lower risk and slower disease progression.
Another major development: shortly after publication, we learned that the scans Cleerly was analyzing were not fully blinded. In studies like this, the order of scans is typically kept unknown to the analyst to help prevent any potential for bias. But in this case, the chronological order was available in the scans. We therefore asked Cleerly to repeat their analysis using a properly blinded set of scans, which is standard practice in longitudinal studies. Cleerly declined to perform a blinded reanalysis.
Because of this, we commissioned an additional, independent analysis from Heartflow. Heartflow has been a leader in this space and is the most extensively validated AI platform for coronary CTA analysis.
The Heartflow analysis was conducted with full operational blinding and completed right before the prespecified third, and final quantitative analysis, which uses Medis QAngio. These two independent platforms were consistent with each other, yet both differed substantially from the Cleerly results.
As these independent results became available, we shared them privately with Cleerly and again requested a blinded reanalysis of their original work. We offered to cover any costs involved just in case this was the barrier to reanalysis. Cleerly again declined.
However, a new development emerged. Several participants requested their scans from the study and submitted them directly through their own, personal cardiologist. Any cardiologist with a proper Cleerly account can appropriately submit scans on their patient's behalf.
So in a sense, our participants themselves were able to provide a portion of the blinded analysis we were originally requesting. This was then shared with me on behalf of the Citizen Science Foundation. In total, there are 19 of these individual submissions — about 10% of the total scans in our study so far.
Individual Submissions vs. Study Data
We focused on the 8 participants who have both a baseline and a follow-up individual submission of their scans (the other 3 submissions are unpaired).
[Please Note: These data are preliminary]
Figure 1 compares the change in soft plaque (Non-Calcified Plaque Volume or NCPV) reported by the original Cleerly study analysis against the results from each participant's individual submission. [See Figure 1]
Of the 8 participants, four showed an increase in soft plaque in both datasets — but in three of those four cases, the individual submissions reported substantially less progression than the study data. The remaining four participants all showed progression in the study data, yet every one of their individual submissions showed a decrease — a complete reversal of direction. The largest discrepancy was a single participant whose study data reported an increase of 32 mm³, while their individual submission showed a decrease of 48 mm³ — a reversal of approximately 80 mm³.
The median change in soft plaque for these 8 participants was +20.6 mm³ (a 31% increase) in the original study data, compared to just +0.7 mm³ (about a 2% increase) from their individual submissions (Figure 2).
The mean average is even more pronounced: the study data shows an average increase of +20.9 mm³ (42% from baseline), while the individual submissions show an average decrease of 5.1 mm³ (an 8% decline). In other words, the study data says plaque went up; the individual submissions say it went down (Figure 3).
Direction of Change Across Platforms
To put these individual submissions in broader context, Figure 4 compares the direction of soft plaque change across three analyses of these same scans.
On the left is the original Cleerly study analysis — 99 participants after excluding one who had a procedure between scans. 98% showed an increase in soft plaque. Only 2 showed no change. Zero showed regression.
In the middle are the 8 individual submissions, split right down the middle: 50% showing progression and 50% showing regression. On the right is the full Heartflow analysis across 95 participants.
While 8 is a small sample size, the direction-of-change in these individual submissions is far closer to the Heartflow analysis than the original Cleerly analysis. It is worth emphasizing: 4 out of the 8 participants — fully half — received individual submission results showing less plaque in their second scan than their first. But after accounting for the single exclusion mentioned above, not one of the 99 participants in the original Cleerly study analysis showed plaque regression.
We are not sure what happened with the original Cleerly analysis. We just know the other analyses are largely consistent with each other — and now, that includes these individual submissions to Cleerly as well.
Next Steps
We have already taken steps regarding last year's paper that contained the original Cleerly analysis. We are working with the journal on that now, and we expect news on this very soon.
In the meantime, the preprint of our current paper with both Heartflow and QAngio results is available at the link below.
Importantly, the two principal findings reported in the original paper have been reproduced in both the Heartflow and QAngio analyses:
(1) baseline plaque strongly predicts future plaque progression, and
(2) ApoB was not associated with plaque progression
I want to once again thank Dr. Budoff and the Lundquist team for providing these scans to study participants who request them.
If you are a participant in our study and interested in sending in your scans through your cardiologist, we now have a budget to help cover the cost of that submission. You can contact us at info@citizensciencefoundation.org for more details.
Thank you again to everyone for your support. 🙏
cc @nicknorwitz @AdrianSotoMota](https://pbs.twimg.com/media/HCX8j46a4AAib6Q.png)
![realDaveFeldman's tweet photo. I want to share a crucial update on our study, KETO-CTA.
(The video for this article is in the next tweet)
Our study recruited 100 participants, each undergoing two high-resolution heart scans, known as CT angiograms, one year apart. (For more background on this study design, see preprint in the following tweet)
There are now four analyses of those same 200 scans. But one of those analyses stands out — and I have some new developments to report.
For a quick background, the first quantitative analysis was from an AI company, Cleerly. We published their analysis of our scans last year.
After the paper was published, the Citizen Science Foundation was free to look at the raw Cleerly data, and we found a number of patterns that appeared different from what is typically seen in other coronary plaque studies.
For example, in Cleerly's analysis, not one of the participants showed lower plaque levels at follow-up — even though CTA scans typically show some natural variation in both directions, especially in people who start with very little plaque.
For another example within their data, people with no detectable calcium in their scans appeared to have several times more plaque progression than those who already had some calcium present. This runs counter to what many in cardiology call the "power of zero" — the well-established finding that having no coronary calcium is typically associated with lower risk and slower disease progression.
Another major development: shortly after publication, we learned that the scans Cleerly was analyzing were not fully blinded. In studies like this, the order of scans is typically kept unknown to the analyst to help prevent any potential for bias. But in this case, the chronological order was available in the scans. We therefore asked Cleerly to repeat their analysis using a properly blinded set of scans, which is standard practice in longitudinal studies. Cleerly declined to perform a blinded reanalysis.
Because of this, we commissioned an additional, independent analysis from Heartflow. Heartflow has been a leader in this space and is the most extensively validated AI platform for coronary CTA analysis.
The Heartflow analysis was conducted with full operational blinding and completed right before the prespecified third, and final quantitative analysis, which uses Medis QAngio. These two independent platforms were consistent with each other, yet both differed substantially from the Cleerly results.
As these independent results became available, we shared them privately with Cleerly and again requested a blinded reanalysis of their original work. We offered to cover any costs involved just in case this was the barrier to reanalysis. Cleerly again declined.
However, a new development emerged. Several participants requested their scans from the study and submitted them directly through their own, personal cardiologist. Any cardiologist with a proper Cleerly account can appropriately submit scans on their patient's behalf.
So in a sense, our participants themselves were able to provide a portion of the blinded analysis we were originally requesting. This was then shared with me on behalf of the Citizen Science Foundation. In total, there are 19 of these individual submissions — about 10% of the total scans in our study so far.
Individual Submissions vs. Study Data
We focused on the 8 participants who have both a baseline and a follow-up individual submission of their scans (the other 3 submissions are unpaired).
[Please Note: These data are preliminary]
Figure 1 compares the change in soft plaque (Non-Calcified Plaque Volume or NCPV) reported by the original Cleerly study analysis against the results from each participant's individual submission. [See Figure 1]
Of the 8 participants, four showed an increase in soft plaque in both datasets — but in three of those four cases, the individual submissions reported substantially less progression than the study data. The remaining four participants all showed progression in the study data, yet every one of their individual submissions showed a decrease — a complete reversal of direction. The largest discrepancy was a single participant whose study data reported an increase of 32 mm³, while their individual submission showed a decrease of 48 mm³ — a reversal of approximately 80 mm³.
The median change in soft plaque for these 8 participants was +20.6 mm³ (a 31% increase) in the original study data, compared to just +0.7 mm³ (about a 2% increase) from their individual submissions (Figure 2).
The mean average is even more pronounced: the study data shows an average increase of +20.9 mm³ (42% from baseline), while the individual submissions show an average decrease of 5.1 mm³ (an 8% decline). In other words, the study data says plaque went up; the individual submissions say it went down (Figure 3).
Direction of Change Across Platforms
To put these individual submissions in broader context, Figure 4 compares the direction of soft plaque change across three analyses of these same scans.
On the left is the original Cleerly study analysis — 99 participants after excluding one who had a procedure between scans. 98% showed an increase in soft plaque. Only 2 showed no change. Zero showed regression.
In the middle are the 8 individual submissions, split right down the middle: 50% showing progression and 50% showing regression. On the right is the full Heartflow analysis across 95 participants.
While 8 is a small sample size, the direction-of-change in these individual submissions is far closer to the Heartflow analysis than the original Cleerly analysis. It is worth emphasizing: 4 out of the 8 participants — fully half — received individual submission results showing less plaque in their second scan than their first. But after accounting for the single exclusion mentioned above, not one of the 99 participants in the original Cleerly study analysis showed plaque regression.
We are not sure what happened with the original Cleerly analysis. We just know the other analyses are largely consistent with each other — and now, that includes these individual submissions to Cleerly as well.
Next Steps
We have already taken steps regarding last year's paper that contained the original Cleerly analysis. We are working with the journal on that now, and we expect news on this very soon.
In the meantime, the preprint of our current paper with both Heartflow and QAngio results is available at the link below.
Importantly, the two principal findings reported in the original paper have been reproduced in both the Heartflow and QAngio analyses:
(1) baseline plaque strongly predicts future plaque progression, and
(2) ApoB was not associated with plaque progression
I want to once again thank Dr. Budoff and the Lundquist team for providing these scans to study participants who request them.
If you are a participant in our study and interested in sending in your scans through your cardiologist, we now have a budget to help cover the cost of that submission. You can contact us at info@citizensciencefoundation.org for more details.
Thank you again to everyone for your support. 🙏
cc @nicknorwitz @AdrianSotoMota](https://pbs.twimg.com/media/HCX8ibSbEAAkKJm.png)
![realDaveFeldman's tweet photo. I want to share a crucial update on our study, KETO-CTA.
(The video for this article is in the next tweet)
Our study recruited 100 participants, each undergoing two high-resolution heart scans, known as CT angiograms, one year apart. (For more background on this study design, see preprint in the following tweet)
There are now four analyses of those same 200 scans. But one of those analyses stands out — and I have some new developments to report.
For a quick background, the first quantitative analysis was from an AI company, Cleerly. We published their analysis of our scans last year.
After the paper was published, the Citizen Science Foundation was free to look at the raw Cleerly data, and we found a number of patterns that appeared different from what is typically seen in other coronary plaque studies.
For example, in Cleerly's analysis, not one of the participants showed lower plaque levels at follow-up — even though CTA scans typically show some natural variation in both directions, especially in people who start with very little plaque.
For another example within their data, people with no detectable calcium in their scans appeared to have several times more plaque progression than those who already had some calcium present. This runs counter to what many in cardiology call the "power of zero" — the well-established finding that having no coronary calcium is typically associated with lower risk and slower disease progression.
Another major development: shortly after publication, we learned that the scans Cleerly was analyzing were not fully blinded. In studies like this, the order of scans is typically kept unknown to the analyst to help prevent any potential for bias. But in this case, the chronological order was available in the scans. We therefore asked Cleerly to repeat their analysis using a properly blinded set of scans, which is standard practice in longitudinal studies. Cleerly declined to perform a blinded reanalysis.
Because of this, we commissioned an additional, independent analysis from Heartflow. Heartflow has been a leader in this space and is the most extensively validated AI platform for coronary CTA analysis.
The Heartflow analysis was conducted with full operational blinding and completed right before the prespecified third, and final quantitative analysis, which uses Medis QAngio. These two independent platforms were consistent with each other, yet both differed substantially from the Cleerly results.
As these independent results became available, we shared them privately with Cleerly and again requested a blinded reanalysis of their original work. We offered to cover any costs involved just in case this was the barrier to reanalysis. Cleerly again declined.
However, a new development emerged. Several participants requested their scans from the study and submitted them directly through their own, personal cardiologist. Any cardiologist with a proper Cleerly account can appropriately submit scans on their patient's behalf.
So in a sense, our participants themselves were able to provide a portion of the blinded analysis we were originally requesting. This was then shared with me on behalf of the Citizen Science Foundation. In total, there are 19 of these individual submissions — about 10% of the total scans in our study so far.
Individual Submissions vs. Study Data
We focused on the 8 participants who have both a baseline and a follow-up individual submission of their scans (the other 3 submissions are unpaired).
[Please Note: These data are preliminary]
Figure 1 compares the change in soft plaque (Non-Calcified Plaque Volume or NCPV) reported by the original Cleerly study analysis against the results from each participant's individual submission. [See Figure 1]
Of the 8 participants, four showed an increase in soft plaque in both datasets — but in three of those four cases, the individual submissions reported substantially less progression than the study data. The remaining four participants all showed progression in the study data, yet every one of their individual submissions showed a decrease — a complete reversal of direction. The largest discrepancy was a single participant whose study data reported an increase of 32 mm³, while their individual submission showed a decrease of 48 mm³ — a reversal of approximately 80 mm³.
The median change in soft plaque for these 8 participants was +20.6 mm³ (a 31% increase) in the original study data, compared to just +0.7 mm³ (about a 2% increase) from their individual submissions (Figure 2).
The mean average is even more pronounced: the study data shows an average increase of +20.9 mm³ (42% from baseline), while the individual submissions show an average decrease of 5.1 mm³ (an 8% decline). In other words, the study data says plaque went up; the individual submissions say it went down (Figure 3).
Direction of Change Across Platforms
To put these individual submissions in broader context, Figure 4 compares the direction of soft plaque change across three analyses of these same scans.
On the left is the original Cleerly study analysis — 99 participants after excluding one who had a procedure between scans. 98% showed an increase in soft plaque. Only 2 showed no change. Zero showed regression.
In the middle are the 8 individual submissions, split right down the middle: 50% showing progression and 50% showing regression. On the right is the full Heartflow analysis across 95 participants.
While 8 is a small sample size, the direction-of-change in these individual submissions is far closer to the Heartflow analysis than the original Cleerly analysis. It is worth emphasizing: 4 out of the 8 participants — fully half — received individual submission results showing less plaque in their second scan than their first. But after accounting for the single exclusion mentioned above, not one of the 99 participants in the original Cleerly study analysis showed plaque regression.
We are not sure what happened with the original Cleerly analysis. We just know the other analyses are largely consistent with each other — and now, that includes these individual submissions to Cleerly as well.
Next Steps
We have already taken steps regarding last year's paper that contained the original Cleerly analysis. We are working with the journal on that now, and we expect news on this very soon.
In the meantime, the preprint of our current paper with both Heartflow and QAngio results is available at the link below.
Importantly, the two principal findings reported in the original paper have been reproduced in both the Heartflow and QAngio analyses:
(1) baseline plaque strongly predicts future plaque progression, and
(2) ApoB was not associated with plaque progression
I want to once again thank Dr. Budoff and the Lundquist team for providing these scans to study participants who request them.
If you are a participant in our study and interested in sending in your scans through your cardiologist, we now have a budget to help cover the cost of that submission. You can contact us at info@citizensciencefoundation.org for more details.
Thank you again to everyone for your support. 🙏
cc @nicknorwitz @AdrianSotoMota](https://pbs.twimg.com/media/HCX8ebga0AARj_o.png)
Olivia
Online
SuccessfulKetoLifestyle
@SuccessfulKeto
Free ketogenic support group. We meet on Zoom 6 days a week.
Joined March 2023
73 Following
35 Followers
213 Posts
Heart disease is the number one worldwide killer and has been for a long time, and the data is very clear poor metabolic health is at the root cause of heart disease.
@matthewbaszucki We recommend high fat ketovore or high fat carnivore for our group members using ketosis for mental health. Sometimes too much restriction, too quickly can flare up food addiction disorders or depression. We walk the journey with our group members, all for free on FB and Zoom.
Ketosis doesn't feel like a diet.
It feels like someone finally turned the lights on in a room you'd been navigating in the dark for years.
The first time my brain ran on ketones instead of glucose, I had more mental clarity than I'd ever experienced. That's not an exaggeration. Even on five bipolar meds.
Within a few weeks of strict keto, my manic episodes stopped happening. I haven't been hospitalized since.
@annmforti Congratulations! That is so wonderful to hear! We help people get into therapeutic nutritional ketosis and stay there, for various health reasons including epilepsy and mental health. If anyone needs help join us on Facebook, it's 100% free.
What do Harvard, Oxford, Stanford, Univ of Edinburgh, Mayo Clinic, Ohio State, James Cook, UCSF, and UCSD share in common?
They are all conducting trials of ketogenic diets for mental illness.
The results could change the field of psychiatry.
@DeborahKnox @ChrisPalmerMD We support people to get to therapeutic nutritional ketosis with a high fat ketovore approach & we have seen improvements in chronic kidney disease & reversal of fatty liver disease. After the 3 phases of adaptation a person will eat less and less & let the chemistry carry them.
@ChrisPalmerMD You are walking the talk and inspiring others. We have noticed an uptick of psychiatry practitioners joining our support group recently. We teach therapeutic nutritional ketosis and have been helping people for over 6 years navigate the keto journey. You're our hero!
We are on Day 3 of 35 Days of FREE Support and Accountability! There is still time to join! We do this three times per year and just in 3 days we have seen amazing results from our members with reduced blood glucose, reduced inflammation and weight loss! Join us on Facebook!
@ChrisPalmerMD Cannot believe anyone would use that term. You're the exact opposite! Just know that whatever you face in this lifetime, it's a test and you have passed by helping humanity. The pearly gates are waiting for you and your legacy will live on forever due to your work!
@abdullaenazi76 @ChrisPalmerMD Don't think of it as a diet. It is a way of eating (WoE) for the rest of your life to keep your symptoms in remission. Make it a part of your lifestyle that works for you. You'll be glad you did!
The biggest shift in cardiovascular prevention in years just dropped — and almost no one is talking about it.
As a medical school professor, I've watched heart disease stay America's #1 killer for decades. New AHA/ACC guidelines finally move the line.
What changed (via Harvard Gazette):
- Risk assessment now starts at age 30, not 40-50
- Universal lipid screening in children ages 9-11
- Lp(a) screening — elevated in 20% of people, 6x stickier than LDL
- Coronary calcium and polygenic risk are now formal tools
- Treatment threshold dropped to 3% 10-year risk (was 5%)
- Old calculator overpredicted risk by 40-50%
Striking line: ~80% of cardiovascular disease is preventable through lifestyle.
This is the shift I argue for in "Lies I Taught in Medical School" — treat metabolic disease at the roots, not at the event.
Metabolic dysfunction is the root cause of chronic disease. Heart disease is the downstream bill.
Full breakdown coming on the Health Longevity Secrets podcast https://t.co/VbpysB6bJs
Source: https://t.co/pFsPUm07TX
#HeartDisease #Prevention #MetabolicHealth #HealthLongevitySecrets
Truly humbled. 🙏
Our documentary, The Cholesterol Code, is now officially released to streaming on @amazon and I couldn't be happier with the feedback we've been getting -- every single hour.
🙏 I really want to take a moment to thank some very important people who made this possible:
@wideeyetv -- and in particular, our Director - Jen Isenhart, our DP - Tom Hadzor, and our Editor - Bill Krumm
@Metabolic_Mind -- in particular, the incomparable @janellison
My best very good friends and collaborators, @nicknorwitz & @AdrianSotoMota
There are definitely many, many more people to thank which I'll be doing a lot more of tomorrow for the super stream.
The video can be found here: https://t.co/Pvl4tZ0Afb
Preprint link here:
I want to share a crucial update on our study, KETO-CTA.
(The video for this article is in the next tweet)
Our study recruited 100 participants, each undergoing two high-resolution heart scans, known as CT angiograms, one year apart. (For more background on this study design, see preprint in the following tweet)
There are now four analyses of those same 200 scans. But one of those analyses stands out — and I have some new developments to report.
For a quick background, the first quantitative analysis was from an AI company, Cleerly. We published their analysis of our scans last year.
After the paper was published, the Citizen Science Foundation was free to look at the raw Cleerly data, and we found a number of patterns that appeared different from what is typically seen in other coronary plaque studies.
For example, in Cleerly's analysis, not one of the participants showed lower plaque levels at follow-up — even though CTA scans typically show some natural variation in both directions, especially in people who start with very little plaque.
For another example within their data, people with no detectable calcium in their scans appeared to have several times more plaque progression than those who already had some calcium present. This runs counter to what many in cardiology call the "power of zero" — the well-established finding that having no coronary calcium is typically associated with lower risk and slower disease progression.
Another major development: shortly after publication, we learned that the scans Cleerly was analyzing were not fully blinded. In studies like this, the order of scans is typically kept unknown to the analyst to help prevent any potential for bias. But in this case, the chronological order was available in the scans. We therefore asked Cleerly to repeat their analysis using a properly blinded set of scans, which is standard practice in longitudinal studies. Cleerly declined to perform a blinded reanalysis.
Because of this, we commissioned an additional, independent analysis from Heartflow. Heartflow has been a leader in this space and is the most extensively validated AI platform for coronary CTA analysis.
The Heartflow analysis was conducted with full operational blinding and completed right before the prespecified third, and final quantitative analysis, which uses Medis QAngio. These two independent platforms were consistent with each other, yet both differed substantially from the Cleerly results.
As these independent results became available, we shared them privately with Cleerly and again requested a blinded reanalysis of their original work. We offered to cover any costs involved just in case this was the barrier to reanalysis. Cleerly again declined.
However, a new development emerged. Several participants requested their scans from the study and submitted them directly through their own, personal cardiologist. Any cardiologist with a proper Cleerly account can appropriately submit scans on their patient's behalf.
So in a sense, our participants themselves were able to provide a portion of the blinded analysis we were originally requesting. This was then shared with me on behalf of the Citizen Science Foundation. In total, there are 19 of these individual submissions — about 10% of the total scans in our study so far.
Individual Submissions vs. Study Data
We focused on the 8 participants who have both a baseline and a follow-up individual submission of their scans (the other 3 submissions are unpaired).
[Please Note: These data are preliminary]
Figure 1 compares the change in soft plaque (Non-Calcified Plaque Volume or NCPV) reported by the original Cleerly study analysis against the results from each participant's individual submission. [See Figure 1]
Of the 8 participants, four showed an increase in soft plaque in both datasets — but in three of those four cases, the individual submissions reported substantially less progression than the study data. The remaining four participants all showed progression in the study data, yet every one of their individual submissions showed a decrease — a complete reversal of direction. The largest discrepancy was a single participant whose study data reported an increase of 32 mm³, while their individual submission showed a decrease of 48 mm³ — a reversal of approximately 80 mm³.
The median change in soft plaque for these 8 participants was +20.6 mm³ (a 31% increase) in the original study data, compared to just +0.7 mm³ (about a 2% increase) from their individual submissions (Figure 2).
The mean average is even more pronounced: the study data shows an average increase of +20.9 mm³ (42% from baseline), while the individual submissions show an average decrease of 5.1 mm³ (an 8% decline). In other words, the study data says plaque went up; the individual submissions say it went down (Figure 3).
Direction of Change Across Platforms
To put these individual submissions in broader context, Figure 4 compares the direction of soft plaque change across three analyses of these same scans.
On the left is the original Cleerly study analysis — 99 participants after excluding one who had a procedure between scans. 98% showed an increase in soft plaque. Only 2 showed no change. Zero showed regression.
In the middle are the 8 individual submissions, split right down the middle: 50% showing progression and 50% showing regression. On the right is the full Heartflow analysis across 95 participants.
While 8 is a small sample size, the direction-of-change in these individual submissions is far closer to the Heartflow analysis than the original Cleerly analysis. It is worth emphasizing: 4 out of the 8 participants — fully half — received individual submission results showing less plaque in their second scan than their first. But after accounting for the single exclusion mentioned above, not one of the 99 participants in the original Cleerly study analysis showed plaque regression.
We are not sure what happened with the original Cleerly analysis. We just know the other analyses are largely consistent with each other — and now, that includes these individual submissions to Cleerly as well.
Next Steps
We have already taken steps regarding last year's paper that contained the original Cleerly analysis. We are working with the journal on that now, and we expect news on this very soon.
In the meantime, the preprint of our current paper with both Heartflow and QAngio results is available at the link below.
Importantly, the two principal findings reported in the original paper have been reproduced in both the Heartflow and QAngio analyses:
(1) baseline plaque strongly predicts future plaque progression, and
(2) ApoB was not associated with plaque progression
I want to once again thank Dr. Budoff and the Lundquist team for providing these scans to study participants who request them.
If you are a participant in our study and interested in sending in your scans through your cardiologist, we now have a budget to help cover the cost of that submission. You can contact us at [email protected] for more details.
Thank you again to everyone for your support. 🙏
cc @nicknorwitz @AdrianSotoMota
![realDaveFeldman's tweet photo. I want to share a crucial update on our study, KETO-CTA.
(The video for this article is in the next tweet)
Our study recruited 100 participants, each undergoing two high-resolution heart scans, known as CT angiograms, one year apart. (For more background on this study design, see preprint in the following tweet)
There are now four analyses of those same 200 scans. But one of those analyses stands out — and I have some new developments to report.
For a quick background, the first quantitative analysis was from an AI company, Cleerly. We published their analysis of our scans last year.
After the paper was published, the Citizen Science Foundation was free to look at the raw Cleerly data, and we found a number of patterns that appeared different from what is typically seen in other coronary plaque studies.
For example, in Cleerly's analysis, not one of the participants showed lower plaque levels at follow-up — even though CTA scans typically show some natural variation in both directions, especially in people who start with very little plaque.
For another example within their data, people with no detectable calcium in their scans appeared to have several times more plaque progression than those who already had some calcium present. This runs counter to what many in cardiology call the "power of zero" — the well-established finding that having no coronary calcium is typically associated with lower risk and slower disease progression.
Another major development: shortly after publication, we learned that the scans Cleerly was analyzing were not fully blinded. In studies like this, the order of scans is typically kept unknown to the analyst to help prevent any potential for bias. But in this case, the chronological order was available in the scans. We therefore asked Cleerly to repeat their analysis using a properly blinded set of scans, which is standard practice in longitudinal studies. Cleerly declined to perform a blinded reanalysis.
Because of this, we commissioned an additional, independent analysis from Heartflow. Heartflow has been a leader in this space and is the most extensively validated AI platform for coronary CTA analysis.
The Heartflow analysis was conducted with full operational blinding and completed right before the prespecified third, and final quantitative analysis, which uses Medis QAngio. These two independent platforms were consistent with each other, yet both differed substantially from the Cleerly results.
As these independent results became available, we shared them privately with Cleerly and again requested a blinded reanalysis of their original work. We offered to cover any costs involved just in case this was the barrier to reanalysis. Cleerly again declined.
However, a new development emerged. Several participants requested their scans from the study and submitted them directly through their own, personal cardiologist. Any cardiologist with a proper Cleerly account can appropriately submit scans on their patient's behalf.
So in a sense, our participants themselves were able to provide a portion of the blinded analysis we were originally requesting. This was then shared with me on behalf of the Citizen Science Foundation. In total, there are 19 of these individual submissions — about 10% of the total scans in our study so far.
Individual Submissions vs. Study Data
We focused on the 8 participants who have both a baseline and a follow-up individual submission of their scans (the other 3 submissions are unpaired).
[Please Note: These data are preliminary]
Figure 1 compares the change in soft plaque (Non-Calcified Plaque Volume or NCPV) reported by the original Cleerly study analysis against the results from each participant's individual submission. [See Figure 1]
Of the 8 participants, four showed an increase in soft plaque in both datasets — but in three of those four cases, the individual submissions reported substantially less progression than the study data. The remaining four participants all showed progression in the study data, yet every one of their individual submissions showed a decrease — a complete reversal of direction. The largest discrepancy was a single participant whose study data reported an increase of 32 mm³, while their individual submission showed a decrease of 48 mm³ — a reversal of approximately 80 mm³.
The median change in soft plaque for these 8 participants was +20.6 mm³ (a 31% increase) in the original study data, compared to just +0.7 mm³ (about a 2% increase) from their individual submissions (Figure 2).
The mean average is even more pronounced: the study data shows an average increase of +20.9 mm³ (42% from baseline), while the individual submissions show an average decrease of 5.1 mm³ (an 8% decline). In other words, the study data says plaque went up; the individual submissions say it went down (Figure 3).
Direction of Change Across Platforms
To put these individual submissions in broader context, Figure 4 compares the direction of soft plaque change across three analyses of these same scans.
On the left is the original Cleerly study analysis — 99 participants after excluding one who had a procedure between scans. 98% showed an increase in soft plaque. Only 2 showed no change. Zero showed regression.
In the middle are the 8 individual submissions, split right down the middle: 50% showing progression and 50% showing regression. On the right is the full Heartflow analysis across 95 participants.
While 8 is a small sample size, the direction-of-change in these individual submissions is far closer to the Heartflow analysis than the original Cleerly analysis. It is worth emphasizing: 4 out of the 8 participants — fully half — received individual submission results showing less plaque in their second scan than their first. But after accounting for the single exclusion mentioned above, not one of the 99 participants in the original Cleerly study analysis showed plaque regression.
We are not sure what happened with the original Cleerly analysis. We just know the other analyses are largely consistent with each other — and now, that includes these individual submissions to Cleerly as well.
Next Steps
We have already taken steps regarding last year's paper that contained the original Cleerly analysis. We are working with the journal on that now, and we expect news on this very soon.
In the meantime, the preprint of our current paper with both Heartflow and QAngio results is available at the link below.
Importantly, the two principal findings reported in the original paper have been reproduced in both the Heartflow and QAngio analyses:
(1) baseline plaque strongly predicts future plaque progression, and
(2) ApoB was not associated with plaque progression
I want to once again thank Dr. Budoff and the Lundquist team for providing these scans to study participants who request them.
If you are a participant in our study and interested in sending in your scans through your cardiologist, we now have a budget to help cover the cost of that submission. You can contact us at info@citizensciencefoundation.org for more details.
Thank you again to everyone for your support. 🙏
cc @nicknorwitz @AdrianSotoMota](https://pbs.twimg.com/media/HCX8mTYb0AA7Unn.jpg)
I feel like I can breathe again! Get ready for a rant I've been waiting to let loose for a year. 🔥
First, here are the core facts about the Keto-CTA study to date:
🚨PART 1: THE FACTS
👉From its inception, Dave, Adrian, and I, being associated via the funding body (the Citizen Science Foundation), were blinded to certain elements of the data. The purpose was to protect the integrity of the project.
👉The profound irony is this also meant that, prior to publication, we couldn’t perform certain ‘checks’ and had to trust others to do so. Speaking for myself, it’s now painfully clear that was a mistake.
👉However, after the April 7th paper was published, "anomalies" (if I’m being polite) were noted with the Cleerly scans.
👉 Cleerly refused to redo the scans, despite multiple requests and being offered payment.
👉Importantly, and to my dismay, the original Cleerly reads were UNBLINDED, introducing a major source of bias.
👉At additional expensive, the scans were rerun through HeartFlow in a properly blinded analysis, and via the pre-specified QAngio methodology.
👉HeartFlow and QAngio agreed with each other and were discordant with the Cleerly analysis.
🚨PART 2: THE NEW NEWS
What happened next was brilliant!
And, truth be told, I only found out about it yesterday.
For my own legal security – and at the recommendation of my friend and colleague who was taking the worst of it on the back end – there was a lot I didn’t know until this point.
This is what happened…
👉Several participants independently submitted their scans to Cleerly as a workaround to obtain a truly blinded Cleerly analysis.
👉Those results were highly discordant with the original Cleerly analysis and aligned with the HeartFlow and QAngio analyses.
The difference between the original Cleerly scans and the repeated blinded scans was massive!
The original unblinded analysis reported a +20.9 mm³ mean increase in non-calcified plaque volume, while the blinded repeats showed a -5.1 mm³ mean decrease.
I mean, MY GOODNESS!!! I basically did a backflip when I found out (@realDaveFeldman can release the footage of the meeting at his discretion)
If you’ve been following the KETO-CTA story up to this point, the consistency of the findings across HeartFlow, QAngio, and now Cleerly itself (based on the blinded reads) should bring much-needed clarity.
The converging results fundamentally reshape the narrative and directly refute the claim that the study demonstrates massive, unprecedented plaque progression in LMHR and near-LMHR
And, after all that, the fact remains that every single analysis found no association between ApoB levels or LDL exposure and plaque progression.
LET ME REPEAT: And, after all that, the fact remains that every single analysis found no association between ApoB levels or LDL exposure and plaque progression.
🚨 PART 3: NEXT STEPS
In terms of next steps, I’ll quote my colleague Dave: “we have already taken steps regarding last year’s paper that contained the original Cleerly analysis.” I’ll leave it at that for now so I don’t overstep.
But let me say, that’s the highly polished and diplomatic version. I certainly have stronger words about this process, but perhaps now is not the time.
Where I will speak more plainly is in regard to the behavior of some detractors over the past several months.
In a few cases, I’ve reached out privately to individuals who should know better, gently suggesting that, in light of the new evidence (Heartflow and QAngio), it might be time to reassess or lighten the abuse.
For anyone sincerely paying attention—and for anyone with even modest insight into how scientific bureaucracy works—I hope it is now clear why we were not more forthcoming earlier in the process.
👉And trust me when I say, it’s never been harder to keep my mouth shut about anything in my life. I've accumulated more cortisol AUC in the last 11 months then in the entirety of my life to age 29.
🚨PART 4: SPEAKING FOR MYSELF
Speaking for myself, I have been beyond frustrated and disappointed.
At multiple stages, it has become painfully—and increasingly—clear to me that our scientific system, which presents itself as purely meritocratic, is far more political than most would imagine.
These are difficult words for me to say as someone who comes from a family of doctors and scientists and who has spent his entire career in academic institutions—multiple Ivy League universities @Harvard @dartmouth, two doctorates, and top-ranked institutions in both England @UniofOxford and the United States. I was groomed in conventional academic medicine. If I have any bias, it’s to see the best in conventional medicine and modern scientific process. Most of my loved ones have made their living within this ecosystem.
But when you pull back the curtain, the reality can be sobering.
To those detractors who have verbally abused or personally attacked my colleagues and me—perhaps out of naivete or ignorance—I will say this plainly: it’s time to check yourselves.
Too many people have spoken out of turn, seemingly to score points rather than to engage thoughtfully with an evolving scientific story—one that has been evolving for quite some time.
When the HeartFlow and QAngio analyses were released, that alone should have prompted serious reflection. At minimum, it should have raised questions. The subsequent silence from some of the loudest critics, after they believed they had “won” a round, is telling.
Science deserves better than scorekeeping. It deserves intellectual honesty and the humility to update one’s position when new evidence emerges. At times over the last year, the lack of curiosity, sincerity, and intellectual honesty from people who I tried to give the benefit of the doubt has made me want to vomit.
And trust me when I say, this isn’t a victory lap.
This is a promise.
We are now over a hurdle that I have been waiting for almost a year. And frankly, I am ready to run headfirst through brick walls with my colleagues and friends by my side — those whom I trust to pursue the hard questions and the honest answers — and do so indefinitely using the tools and resources at our disposal, even when, and especially when, the scales are improperly tilted against us.
Lucky for us, the intellectual environment is expanding — the black box of academia beginning to crack open. So someone hand me a crowbar, because I’m committing myself fully and completely, over the coming years and decades, to prying it wide open. Not gently. Not quietly. But decisively.
My final words of this verbose dissertation?
LFG
@ChrisPalmerMD 2/2 Many of our support group members with anxiety, depression, PTSD find that they can ween down or completely off of meds with ketogenic diet and working with their doc. Staying off the meds requires consistent therapeutic nutritional ketosis.
@ChrisPalmerMD Thank you @ChrisPalmerMD, this is a great post and is consistent with what we have found in our Keto Support Group over the last 5 years. Bi-polar & schizophrenia patients can get remission of symptoms but still rely on low doses of meds & coordination with their docs. 1/2
I've never received as much attention from the press as over the past two weeks, all centered around one question:
Can keto "cure" schizophrenia?
Here's my nuanced response to this question.
https://t.co/4Xg7DDZfag
@lowcarbGP It's time for human studies for human physiology. We have 1700 people in our free ketogenic support group that trust a ketogenic diet will improve their health. We meet daily, help them understand their bloodwork and how the keto chemistry works. Use humans for this science!
@nicknorwitz Here is the perfect date night cheesecake to make. It's complex and requires a good amount of effort and time. It's layered & I call it the "5-hour Cheesecake" because you cook one layer before adding the next. https://t.co/7fRZWIMsdr
Last Seen Users on Sotwe
Seksek116
Seen from Turkey
Alice 
Seen from United States
Nguyễn Huỳnh Phúc Lộc
Seen from Vietnam
RealRawNews
Big Cock Boys (XXL) ❌ The Best X Men 🤯😈🍆
Seen from Mexico
Van
Seen from United States
Glamourpussyy’s Shit
Seen from United States
An Huy
Seen from Vietnam
MammaryMania（ ͜•人 ͜•）
Seen from Turkey
thichsuccu
Seen from Australia
Most Popular Users
Elon Musk
@elonmusk
240.3M followers
Barack Obama
@barackobama
119.2M followers
Donald J. Trump
@realdonaldtrump
111.6M followers
Cristiano Ronaldo
@cristiano
109.6M followers
Narendra Modi
@narendramodi
106.9M followers
Rihanna
@rihanna
97.4M followers
NASA
@nasa
92.1M followers
Justin Bieber
@justinbieber
90.7M followers
KATY PERRY
@katyperry
87.1M followers
Taylor Swift
@taylorswift13
81M followers
Lady Gaga
@ladygaga
72.5M followers
Kim Kardashian
@kimkardashian
69.5M followers
Virat Kohli
@imvkohli
69.1M followers
YouTube
@youtube
68.6M followers
Bill Gates
@billgates
63.6M followers
The Ellen Show
@theellenshow
62.5M followers
CNN
@cnn
61.9M followers
Neymar Jr
@neymarjr
61.7M followers
X
@x
60.9M followers
Selena Gomez
@selenagomez
60.2M followers